These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

392 related items for PubMed ID: 7845006

  • 1. Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular bcr-abl protein levels.
    Smetsers TF, van de Locht LT, Pennings AH, Wessels HM, de Witte TM, Mensink EJ.
    Leukemia; 1995 Jan; 9(1):118-30. PubMed ID: 7845006
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.
    Mahon FX, Ripoche J, Pigeonnier V, Jazwiec B, Pigneux A, Moreau JF, Reiffers J.
    Exp Hematol; 1995 Dec; 23(14):1606-11. PubMed ID: 8542954
    [Abstract] [Full Text] [Related]

  • 4. Phosphorothioate-capped antisense oligonucleotides to Ras GAP inhibit cell proliferation and trigger apoptosis but fail to downregulate GAP gene expression.
    White JR, Gordon-Smith EC, Rutherford TR.
    Biochem Biophys Res Commun; 1996 Oct 03; 227(1):118-24. PubMed ID: 8858112
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
    Wu AG, Joshi SS, Chan WC, Iversen PL, Jackson JD, Kessinger A, Pirruccello SJ, Sanger WG, Sharp JG, Verbik DJ.
    Leuk Lymphoma; 1995 Dec 03; 20(1-2):67-76. PubMed ID: 8750625
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.
    Skorski T, Nieborowska-Skorska M, Wlodarski P, Perrotti D, Hoser G, Kawiak J, Majewski M, Christensen L, Iozzo RV, Calabretta B.
    J Natl Cancer Inst; 1997 Jan 15; 89(2):124-33. PubMed ID: 8998181
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. An antisense Bcr-Abl phosphodiester-tailed methylphosphonate oligonucleotide reduces the growth of chronic myeloid leukaemia patient cells by a non-antisense mechanism.
    Smetsers TF, Linders EH, van de Locht LT, de Witte TM, Mensink EJ.
    Br J Haematol; 1997 Feb 15; 96(2):377-81. PubMed ID: 9029029
    [Abstract] [Full Text] [Related]

  • 12. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.
    Wetzler M, Talpaz M, Van Etten RA, Hirsh-Ginsberg C, Beran M, Kurzrock R.
    J Clin Invest; 1993 Oct 15; 92(4):1925-39. PubMed ID: 8408645
    [Abstract] [Full Text] [Related]

  • 13. Antisense inhibition of P210 bcr-abl in chronic myeloid leukemia.
    Vaerman JL, Lewalle P, Martiat P.
    Stem Cells; 1993 Oct 15; 11 Suppl 3():89-95. PubMed ID: 8298481
    [Abstract] [Full Text] [Related]

  • 14. Circular antisense oligonucleotides inhibit growth of chronic myeloid leukemia cells.
    Rowley PT, Kosciolek BA, Kool ET.
    Mol Med; 1999 Oct 15; 5(10):693-700. PubMed ID: 10602778
    [Abstract] [Full Text] [Related]

  • 15. Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides.
    Skórski T, Szczylik C, Malaguarnera L, Calabretta B.
    Folia Histochem Cytobiol; 1991 Oct 15; 29(3):85-9. PubMed ID: 1794439
    [Abstract] [Full Text] [Related]

  • 16. The repression of apoptosis by activated abl oncogenes in chronic myelogenous leukaemia.
    Fernandes RS, Gorman AM, McGahon A, Lawlor M, McCann S, Cotter TG.
    Leukemia; 1996 Jun 15; 10 Suppl 2():s17-21. PubMed ID: 8649049
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Capping of bcr-abl antisense oligonucleotides enhances antiproliferative activity against chronic myeloid leukemia cell lines.
    Thomas M, Kosciolek B, Wang N, Rowley P.
    Leuk Res; 1994 Jun 15; 18(6):401-8. PubMed ID: 8207957
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines.
    Algar EM, Khromykh T, Smith SI, Blackburn DM, Bryson GJ, Smith PJ.
    Oncogene; 1996 Mar 07; 12(5):1005-14. PubMed ID: 8649791
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.